What is this, in one plain sentence?
Klippel-Trenaunay Syndrome is a congenital combined slow-flow vascular malformation syndrome — a PIK3CA-driven condition producing capillary, venous, and often lymphatic malformations together, typically in one limb, with a port wine stain, abnormal veins, and variable soft tissue and bone overgrowth.
What causes it?
The molecular driver in most KTS cases is a somatic activating mutation in PIK3CA, which encodes the p110α catalytic subunit of phosphatidylinositol 3-kinase. This activates the PI3K/AKT/mTOR pathway — the same pathway driving CLOVES syndrome, FAVA, isolated lymphatic malformations, and other PROS-spectrum conditions. The mutation is mosaic: present in some cells, absent in others, arising during embryonic development. This explains why KTS is typically unilateral and segmental.
Not all KTS cases carry identified PIK3CA mutations. Some may involve other genetic mechanisms. Genetic testing from affected tissue — not blood — is needed to confirm PIK3CA involvement and inform sirolimus therapy decisions.
How does it present?
Presentation varies substantially. The classic triad — port wine stain, varicose veins, limb hypertrophy — appears in full in some patients and partially in others. Key clinical features include: geographic capillary malformation on the affected limb; lateral varicose veins including the persistent vein of Servelle; limb length discrepancy; soft tissue hypertrophy; lymphedema; and pain — particularly with exertion, dependency, or menstrual cycles. DVT risk is elevated. GI and GU involvement occurs in some patients. Localized intravascular coagulopathy (LIC) requires monitoring.
How is it diagnosed?
| Doppler Ultrasound | First-line. Identifies venous anatomy, reflux, and — critically — confirms slow-flow. Rules out AV shunting. |
| MRI / MR Venography | Defines full malformation extent, soft tissue involvement, lymphatic anomalies. Essential for planning. |
| MR Angiography | Rules out AV shunting definitively. KTS diagnosis is confirmed by its absence. |
| PIK3CA Genetic Testing | From affected tissue (not blood). Guides sirolimus therapy decisions. |
What are the treatment options?
| Compression Therapy | First-line — venous and lymphatic components. Custom graduated garments. Daily, lifelong. |
| Sclerotherapy | Image-guided for venous and lymphatic malformations. Experienced interventional radiologist at a VA center. |
| PDL Laser | For the surface capillary malformation only. Does not treat venous, lymphatic, or overgrowth components. |
| Sirolimus | Systemic mTOR inhibitor for complex or refractory PROS cases. Particularly for significant lymphatic involvement. Specialist management required. |
| Surgical Debulking | For functional impairment from overgrowth. Selected cases. |
| Orthopedic Management | Limb length discrepancy — orthotics, epiphysiodesis in growing children with significant discrepancy. |
| DVT / LIC Management | Anticoagulation as indicated. Pre-operative planning essential. Pregnancy requires specialist co-management. |
What are the risks if undertreated?
DVT and pulmonary embolism from venous abnormalities. Significant limb length discrepancy causing gait problems and secondary musculoskeletal injury. Lymphedema progression. Bleeding from GI or GU vascular involvement. Coagulopathy triggered by surgery, pregnancy, or prolonged immobility. Pain-driven quality of life impairment. Pregnancy in KTS requires specialist co-management — see prac:000019, prac:000020, prac:000021 (NYU MFM team).
How does it differ from Parkes Weber Syndrome?
| Feature | KTS | Parkes Weber Syndrome |
|---|---|---|
| Flow type | Slow-flow dominant | High-flow — arteriovenous shunting |
| AV fistula / AVM | Absent — defining absence | Present — defining feature |
| Warmth / thrill / bruit | Absent | Often present |
| PDL laser | Safe for capillary component | Contraindicated in high-flow lesions |
| Genetic driver | PIK3CA (PROS) | RASA1 or EPHB4 |
| Treatment approach | Compression, sclerotherapy, sirolimus | Embolization, surgery |
| Hereditary? | No — somatic mosaic | Possibly — genetic counseling indicated |
Source References
| ISSVA Classification | issva.org/classification — 2018, updated 2025 |
| PIK3CA / PROS | Castrén et al. · Castillo et al. — PIK3CA in KTS/CLOVES/FAVA |
| Sirolimus | Adams DM et al. — sirolimus in pediatric vascular anomalies · prac:000002 |
| VAC contributions | Boston Children’s Hospital VAC — prov:000001 |
| Classification evolution | care4rare.blog — Why One Syndrome Became Three |